:format(webp)/YXJ0aWNsZXMvaW1hZ2UvMjAyNS85LzIwMjUwOTI2LWdhZi11NTUtMTcyLmpwZw.webp?w=1920)
Regencell Bioscience Shares Surge 60,000% Since Start of Year
Chinese company Regencell Bioscience claims to possess a patented formula for treating ADHD and autism. Its shares have surged by 60,000% since the start of the year amid intense market demand.
Chinese pharmaceutical company Regencell Bioscience has announced the possession of a patented formula that, according to the firm, can be used to treat Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorders (ASD). Following this announcement, the company's shares have experienced a record-breaking rally — rising 60,000% since the beginning of the year — drawing substantial attention from investors and market participants.
The company specializes in herbal medicine and traditional Chinese therapeutic formulations. Management claims that the formula is a unique therapeutic compound designed to have a comprehensive effect on the nervous system. The medication is currently undergoing trials, and according to Regencell, it has already shown promising results in children diagnosed with ADHD and autism.
Investor interest has skyrocketed following the announcement, fueling unprecedented stock price growth despite limited public data on the research outcomes and regulatory approval stages. The stock’s volatility has been amplified by the limited number of freely traded shares and overall market liquidity.
The company has stated its plans to expand its research efforts and conduct further clinical trials. Regencell representatives also announced their intention to enter international markets and form partnerships with research institutions in Asia and beyond. They are also considering licensing the technology and signing agreements with major pharmaceutical manufacturers.
Previously, the company had been listed in the U.S. and conducted several market offerings. With shares reaching exceptional levels, the possibility of a stock split is being discussed to make shares more accessible to retail investors. This move could be part of a broader strategy to improve transparency and long-term capitalization.
Despite the extraordinary market performance, experts advise caution. No official data confirming the formula’s efficacy or safety has been released yet. Moreover, the company has not provided information on whether it has completed the full regulatory approval process required for commercial distribution.
Nevertheless, Regencell Bioscience continues to attract attention as one of the fastest-growing stocks of the year, combining biomedical ambition with unconventional approaches to developing therapeutic solutions rooted in traditional practices.
Do you have news that could become a sensation?
Or do you want to try yourself as an editor?
On altn.news , it's possible!
Share your materials, express your opinion, and test your skills as a journalist or editor.
It’s simple:
✅ Download the app:
✅ Register on the website.
✅ Create and publish your news.
Who knows, maybe your material will become the next big headline!
Start today on altn.news.
The editorial board is not responsible for the content and accuracy of material taken, sent or obtained from other sources. The publication of such materials is for informational purposes only and does not imply automatic endorsement or approval of their content.
